Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia

Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia

Abstract Acute myeloid leukemia (AML) is a heterogeneous and complex disease, and treatments for this disease have not been curative for the majority of patients. In younger patients, internal tandem duplication of FLT3 (FLT3-ITD) is a common mutation for which two inhibitors (midostaurin and gilter...

Full description

Bibliographic Details
Main Authors: Lindsey T. Brinton, Pu Zhang, Katie Williams, Daniel Canfield, Shelley Orwick, Steven Sher, Ronni Wasmuth, Larry Beaver, Casey Cempre, Jordan Skinner, Matthew Cannon, Mukul Govande, Bonnie Harrington, Amy Lehman, John C. Byrd, Rosa Lapalombella, James S. Blachly
Format: Article
Language:English
Published: BMC 2020-10-01
Series:Journal of Hematology & Oncology
Subjects:
Gilteritinib
Midostaurin
Synergy
Combination therapy
FLT3
BCL2
Online Access:http://link.springer.com/article/10.1186/s13045-020-00973-4

Internet

http://link.springer.com/article/10.1186/s13045-020-00973-4

Similar Items